M R Posner

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach
    Marshall R Posner
    Department of Medical Oncology, Dana Farber Cancer Institute, SW 430, 44 Binney Street, Boston, MA 02115, USA
    Semin Oncol 31:778-85. 2004
  2. doi request reprint Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer
    Marshall Posner
    Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 35:221-8. 2008
  3. doi request reprint Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation
    M R Posner
    Division of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Oncol 20:921-7. 2009
  4. ncbi request reprint Docetaxel in squamous cell cancer of the head and neck
    M R Posner
    Department of Adult Oncology, Head and Neck Oncology Program, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Drugs 12:S21-4. 2001
  5. ncbi request reprint Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck
    M R Posner
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 19:1096-104. 2001
  6. ncbi request reprint Novel agents for the treatment of mucositis
    Marshall R Posner
    Harvard Medical School, Boston, Massachusetts, USA
    J Support Oncol 5:33-9. 2007
  7. ncbi request reprint Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines
    M R Posner
    The Human Monoclonal Antibody Laboratory, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    Clin Cancer Res 5:2261-70. 1999
  8. pmc Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck
    M R Posner
    Head and Neck Oncology Program, Dana Farber Cancer Institute, SW430H, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 88:11-7. 2003
  9. ncbi request reprint Evolving strategies for combined-modality therapy for locally advanced head and neck cancer
    Marshall Posner
    Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, SW430, Boston, Massachusetts 02115, USA
    Oncologist 12:967-74. 2007
  10. ncbi request reprint Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy
    Marshall R Posner
    Head and Neck Oncology Program, Dana Farber Cancer Institute, 44 Binney Street SW, Suite 430, Boston, Massachusetts 02115 6013, USA
    Oncologist 10:11-9. 2005

Research Grants

Detail Information

Publications83

  1. ncbi request reprint Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach
    Marshall R Posner
    Department of Medical Oncology, Dana Farber Cancer Institute, SW 430, 44 Binney Street, Boston, MA 02115, USA
    Semin Oncol 31:778-85. 2004
    ..ST may represent the cutting edge of therapy for patients with curable, locally advanced SCCHN...
  2. doi request reprint Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer
    Marshall Posner
    Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 35:221-8. 2008
    ..This approach is promising and may have a survival advantage over chemoradiotherapy alone. Both TPF induction and sequential therapy are considered appropriate platforms upon which the new molecularly targeted agents can be tested...
  3. doi request reprint Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation
    M R Posner
    Division of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Oncol 20:921-7. 2009
    ..Locally advanced laryngeal and hypopharyngeal cancers (LHC) represent a group of cancers for which surgery, laryngectomy-free survival (LFS), overall survival (OS), and progression-free survival (PFS) are clinically meaningful end points...
  4. ncbi request reprint Docetaxel in squamous cell cancer of the head and neck
    M R Posner
    Department of Adult Oncology, Head and Neck Oncology Program, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Anticancer Drugs 12:S21-4. 2001
    ..The rate of pathological complete response was also high. The toxicities with TPF therapy were similar to those seen with cisplatin/5-FU regimens without docetaxel. A phase III trial of this approach is currently being conducted...
  5. ncbi request reprint Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck
    M R Posner
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 19:1096-104. 2001
    ....
  6. ncbi request reprint Novel agents for the treatment of mucositis
    Marshall R Posner
    Harvard Medical School, Boston, Massachusetts, USA
    J Support Oncol 5:33-9. 2007
    ..Initial results with selected agents are encouraging, and active research is under way to identify additional new drug targets and candidate drugs, which are reviewed here...
  7. ncbi request reprint Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines
    M R Posner
    The Human Monoclonal Antibody Laboratory, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    Clin Cancer Res 5:2261-70. 1999
    ....
  8. pmc Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck
    M R Posner
    Head and Neck Oncology Program, Dana Farber Cancer Institute, SW430H, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 88:11-7. 2003
    ..The results have significant potential for validating the findings of the phase II studies, demonstrating improved survival and overall response of patients treated with docetaxel-based induction chemotherapy...
  9. ncbi request reprint Evolving strategies for combined-modality therapy for locally advanced head and neck cancer
    Marshall Posner
    Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, SW430, Boston, Massachusetts 02115, USA
    Oncologist 12:967-74. 2007
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  10. ncbi request reprint Paradigm shift in the treatment of head and neck cancer: the role of neoadjuvant chemotherapy
    Marshall R Posner
    Head and Neck Oncology Program, Dana Farber Cancer Institute, 44 Binney Street SW, Suite 430, Boston, Massachusetts 02115 6013, USA
    Oncologist 10:11-9. 2005
    ..Randomized trials comparing a sequential treatment approach with standard therapies are also being undertaken and will likely define a new treatment paradigm for patients with locally advanced head and neck cancer...
  11. ncbi request reprint Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies
    R M Ruprecht
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Transfus Clin Biol 8:350-8. 2001
    ..Future passive immunization studies may reveal other important conserved epitopes...
  12. pmc Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge
    R Hofmann-Lehmann
    Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Virol 75:7470-80. 2001
    ..6P. Thus, combination immunoprophylaxis with passively administered synergistic human MAbs may play a role in the clinical prevention of mother-to-infant transmission of HIV type 1...
  13. ncbi request reprint Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial
    A D Colevas
    Division of Biostatistics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 16:1331-9. 1998
    ..A phase I/II trial of docetaxel, cisplatin, fluorouracil (5-FU), and leucovorin (TPFL5) induction chemotherapy for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)...
  14. ncbi request reprint Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck
    A D Colevas
    Head and Neck Oncology Program and Department of Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 17:3503-11. 1999
    ..To evaluate the toxicity and efficacy of a 4-day regimen of docetaxel, cisplatin, fluorouracil, and leucovorin (TPFL4) in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN)...
  15. doi request reprint Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy
    D J Sher
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA02115, USA
    Ann Oncol 23:2391-8. 2012
    ..Modern radiotherapy typically employs intensity-modulated radiation therapy (IMRT), and herein, we report the Dana-Farber Cancer Institute (DFCI) experience with IMRT-based treatment of OPSCC...
  16. ncbi request reprint Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN)
    A D Colevas
    Head and Neck Oncology Program, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Clin Oncol 25:153-9. 2002
    ..The MTD of opTPFL is 90 mg/m(2) docetaxel. Outpatient administration of opTPFL is tolerable, feasible, and does not alter the ability to administer definitive radiation therapy on schedule...
  17. ncbi request reprint Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma
    Philip C Amrein
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 104:1418-27. 2005
    ....
  18. ncbi request reprint Passive immunization against oral AIDS virus transmission: an approach to prevent mother-to-infant HIV-1 transmission?
    R Hofmann-Lehmann
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 6084, USA
    J Med Primatol 30:190-6. 2001
    ..We conclude that the epitopes recognized by the three mAbs are important determinants for achieving protection. Combination immunoprophylaxis with synergistic mAbs seems promising to prevent maternal HIV-1 transmission in humans...
  19. ncbi request reprint A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck
    A D Colevas
    Head and Neck Oncology Program, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 92:326-31. 2001
    ....
  20. doi request reprint Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
    L J Wirth
    Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA 20114, USA
    Ann Oncol 21:342-7. 2010
    ..Panitumumab has the potential to improve the therapeutic ratio of concurrent chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN)...
  21. ncbi request reprint An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies
    R B Tishler
    Joint Center for Radiation Therapy, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 43:1001-8. 1999
    ..This study examined the feasibility and preliminary results of treating a group of patients using concurrent bolus paclitaxel (Taxol) and radiation therapy...
  22. ncbi request reprint Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment
    Robert Haddad
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Oncologist 8:35-44. 2003
    ....
  23. pmc Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins
    A Li
    Laboratory of Viral Pathogenesis, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Virol 72:3235-40. 1998
    ..We conclude that human MAbs targeting different HIV-1 envelope glycoprotein epitopes exhibit strong synergy when used in combination, a fact that could be exploited clinically for passive immunoprophylaxis against HIV-1...
  24. ncbi request reprint Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
    Marshall R Posner
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 357:1705-15. 2007
    ....
  25. ncbi request reprint Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41
    L A Cavacini
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    AIDS Res Hum Retroviruses 14:1271-80. 1998
    ..Primary structure analysis of the F240 heavy chain revealed strong homology in the CDR domains to an HMAb (3D6) reactive with the same gp41 region, which suggests that these HMAbs could define a potential human antibody clonotype...
  26. doi request reprint Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck
    Anju Parthan
    Mapi Values, 133 Portland Street, Boston, Massachusetts 02114, USA
    Head Neck 31:1255-62. 2009
    ....
  27. pmc Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals
    L A Cavacini
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    J Virol 73:9638-41. 1999
    ..Further dissection of this response should lead to the identification of antibodies and antigenic epitopes for vaccine purposes...
  28. ncbi request reprint Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer
    Laura A Goguen
    Division of Otolaryngology, Department of Surgery, Brigham and Women s Hospital and the Dana Farber Cancer Institute, Boston, MA 02115, USA
    Arch Otolaryngol Head Neck Surg 132:526-31. 2006
    ....
  29. ncbi request reprint Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B
    W Xu
    Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Hum Virol 4:55-61. 2001
    ..Together, our data suggest that passive immunization with currently available anti-clade B mAbs could play a role in preventing HIV clade C transmission through breastfeeding...
  30. ncbi request reprint Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial
    P M Sanz-Altamira
    Division of Hematology Oncology, Boston Center for Liver Cancer, Beth Israel Deaconess Medical Center, Harvard Medical School, Massachusetts, USA
    Dis Colon Rectum 40:770-5. 1997
    ..We examined the efficacy and toxicity of chemoembolization in this setting, identifying prognostic factors to define patients most likely to benefit from the procedure...
  31. doi request reprint Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial
    Jochen H Lorch
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 12:153-9. 2011
    ..We report the long-term results at 5 years' minimum follow-up...
  32. ncbi request reprint A 49-year-old male with locally advanced squamous cell carcinoma of the head and neck: the case for sequential chemoradiotherapy
    Robert Haddad
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 1:58-60; discussion 61-2. 2003
  33. ncbi request reprint Binding and neutralization activity of human IgG1 and IgG3 from serum of HIV-infected individuals
    Lisa A Cavacini
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    AIDS Res Hum Retroviruses 19:785-92. 2003
    ..Understanding isotype and neutralization will provide important data necessary for designing the most effective possible vaccines...
  34. ncbi request reprint Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen
    Lisa A Cavacini
    Beth Israel Deaconess Medical Center, 21 27 Burlington Avenue, Room 556, Boston, MA 02215, USA
    Clin Cancer Res 8:368-73. 2002
    ..Antibodies and cell-mediated immunity, induced by either active or passive immunization, represent potential means to specifically target prostate tumor cells...
  35. ncbi request reprint Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach
    Robert I Haddad
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Am J Clin Oncol 29:153-7. 2006
    ..A retrospective review of primary chemoradiotherapy (CRT) for adenoid cystic carcinoma (ACC) was performed to determine if CRT might be considered as an alternative to radiotherapy and/or definitive surgery...
  36. doi request reprint Seeking alternative biological therapies: the future of targeted molecular treatment
    Jochen H Lorch
    Dana Farber Cancer Institute, 44 Binney Street, SW430, Boston, MA 02115, USA
    Oral Oncol 45:447-53. 2009
    ..This article summarizes the most important recent developments in the targeted treatment of SCCHN and provides an overview of pathways and promising potential targets that could impact the treatment of patients with SCCHN in the future...
  37. doi request reprint Induction chemotherapy in locally advanced head and neck cancer: a new standard of care?
    Jochen H Lorch
    Dana Farber Cancer Institute, SW430, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 22:1155-63, viii. 2008
    ..Studies to enhance the efficacy of TPF induction chemotherapy by adding new targeted agents, such as the EGF-R inhibitors cetuximab and panitumumab, are underway...
  38. ncbi request reprint Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck
    Roy B Tishler
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 65:1036-44. 2006
    ..In a Phase I/II trial, we investigated concurrent weekly docetaxel and concomitant boost radiation in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) after induction chemotherapy...
  39. ncbi request reprint Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer
    Laura A Goguen
    Department of Surgery Division of Otolaryngology, at the Brigham and Women s Hospital and the Dana Farber Cancer Institute, Boston, MA 02115, USA
    Otolaryngol Head Neck Surg 134:916-22. 2006
    ..Assess impact of sequential chemoradiation therapy (SCRT) for advanced head and neck cancer (HNCA) on swallowing, nutrition, and quality of life...
  40. ncbi request reprint Recent advances in combined modality therapy for locally advanced head and neck cancer
    Lori J Wirth
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Curr Cancer Drug Targets 7:674-80. 2007
    ..If the current generation of studies evaluating sequential therapy is favorable, future studies incorporating targeted therapies into this platform will offer further potential for advancing the treatment of SCCHN...
  41. ncbi request reprint Progress and perspectives in chemoprevention of head and neck cancer
    Lori J Wirth
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 3:339-55. 2003
    ..However, barriers to progress in chemoprevention remain, including the validation of surrogate end point biomarkers and identification of safe and well-tolerated agents with the ability to delay carcinogenesis...
  42. ncbi request reprint Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine
    Robert Haddad
    Harvard Medical School, Boston, MA, USA
    Clin Adv Hematol Oncol 1:226-8. 2003
    ....
  43. ncbi request reprint Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck
    Abhay S Gokhale
    Human Monoclonal Antibody Laboratory, Division of Hematology Oncology, Department of Medicine, Room 556, 21 27 Burlington Avenue, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Oral Oncol 41:70-6. 2005
    ..Further, more intensive, study of IL-8 as a biomarker in SCCHN is warranted...
  44. doi request reprint Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck
    Robert I Haddad
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA02115, USA
    J Clin Oncol 27:4448-53. 2009
    ....
  45. ncbi request reprint Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer
    A David McCollum
    Dana Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts, USA
    Head Neck 26:890-6. 2004
    ....
  46. ncbi request reprint Prospective phase II trial of PFL-induction chemotherapy followed by definitive local treatment for advanced squamous cell carcinoma of the head and neck: 10-year follow-up
    Phillip M Devlin
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Clin Oncol 27:369-75. 2004
    ..An organ preservation approach for patients with advanced SCCHN who demonstrated PS CR to chemotherapy demonstrated a trend to improved overall survival...
  47. ncbi request reprint Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer
    Robert Haddad
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Am J Clin Oncol 28:104. 2005
  48. ncbi request reprint Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer
    Robert I Haddad
    Dana Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA 02115, USA
    Expert Rev Anticancer Ther 3:331-8. 2003
    ..Surgery is reserved for advanced nodal-stage disease and for salvage at the primary site. This novel approach has resulted in a higher rate of organ preservation and is ultimately expected to improve survival in this patient population...
  49. pmc Acupuncture for dysphagia after chemoradiation therapy in head and neck cancer: a case series report
    Weidong Lu
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Integr Cancer Ther 9:284-90. 2010
    ..Dysphagia is a common side effect following chemoradiation therapy (CRT) in patients with head and neck cancer (HNC)...
  50. ncbi request reprint Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy
    Lisa A Cavacini
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Med Virol 76:146-52. 2005
    ..Understanding antibody responses to native virions after Clade C infection and cross clade antibody behavior has implications for understanding pathogenesis and vaccine development...
  51. doi request reprint Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer
    David J Sher
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 116:4761-8. 2010
    ..This study reported the experience of the Dana-Farber Cancer Institute (DFCI) with IMRT-based chemoradiotherapy with or without surgery for locally recurrent SCCHN...
  52. ncbi request reprint A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck
    Roy B Tishler
    Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 95:1472-81. 2002
    ..Patients were treated with weekly docetaxel and concurrent daily fractionated radiation therapy to determine the maximum tolerated dose (MTD) of docetaxel and the efficacy of the regimen...
  53. ncbi request reprint Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer
    Beverly A Guadagnolo
    Joint Center for Radiation Therapy, Boston, MA, USA
    Am J Clin Oncol 28:371-8. 2005
    ..The authors reviewed records of patients with advanced laryngeal cancer treated with induction chemotherapy (IC) and hyperfractionated radiation therapy (RT) or chemoradiation (CRT) to determine the rates of organ preservation and function...
  54. pmc Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use
    C S Furniss
    Department of Environmental Health, Harvard School of Public Health, Boston, USA
    Ann Oncol 20:534-41. 2009
    ..The risk of head and neck squamous cell carcinoma (HNSCC) associated with common human papillomavirus types has not been well defined...
  55. ncbi request reprint A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle
    Robert I Haddad
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 10:4680-7. 2004
    ..This Phase II study was conducted to explore the efficacy, safety, and pharmacodynamics of E7070 in squamous cell carcinoma of the head and neck (SCCHN)...
  56. ncbi request reprint The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain
    Luis R Miranda
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    J Immunol 178:7132-8. 2007
    ..These results suggest that structural features of the Ig molecule other than the primary sequence of the variable regions play a more prominent role in HIV neutralization than anticipated...
  57. ncbi request reprint Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck
    Lori J Wirth
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 23:6976-81. 2005
    ..Single-agent targeted therapies have limited activity in this setting. The feasibility of adding celecoxib to gefitinib for the treatment of incurable SCCHN is unknown...
  58. ncbi request reprint Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions
    Lisa A Cavacini
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, BURL 556, Boston, MA 02215, USA
    AIDS 16:2409-17. 2002
    ..Identification of the interactions of human antibodies with virions resulting in neutralization will facilitate vaccine design...
  59. doi request reprint Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy
    Hale B Caglar
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 72:1110-8. 2008
    ..To evaluate early swallowing after intensity-modulated radiotherapy for head and neck squamous cell carcinoma and determine factors correlating with aspiration and/or stricture...
  60. pmc A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils
    Mark Duval
    Beth Israel Deaconess Medical Center, 330 Brookline Avenue, BL556, Boston, MA 02215, USA
    J Virol 82:4671-4. 2008
    ..Therefore, they represent a significant weapon against infection if they can be directed and armed to destroy HIV and infected cells...
  61. ncbi request reprint Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer
    Katie M Applebaum
    Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA
    J Natl Cancer Inst 99:1801-10. 2007
    ..However, it is less clear whether HPV16 influences HNSCC risk associated with alcohol and tobacco use...
  62. ncbi request reprint Head and neck cancer carcinoma: new directions for treatment
    Marshall R Posner
    Head Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    MedGenMed 4:15. 2002
  63. ncbi request reprint CD40 function in squamous cell cancer of the head and neck
    Wenhui Cao
    Human Monoclonal Antibody Laboratory, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Oral Oncol 41:462-9. 2005
    ..CD40 induces secretion of specific proinflammatory and proangiogenic cytokines, inhibits spontaneous and Fas-induced apoptosis and increases EGFr phosphorylation. CD40 signaling may enhance the survival of SCCHN and tumor stroma...
  64. pmc The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects
    D L Mager
    The Forsyth Institute, 140 The Fenway, Boston, MA, USA
    J Transl Med 3:27. 2005
    ..The purpose of the present investigation was to determine if the salivary counts of 40 common oral bacteria in subjects with an oral squamous cell carcinoma (OSCC) lesion would differ from those found in cancer-free (OSCC-free) controls...
  65. ncbi request reprint Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge
    R Hofmann-Lehmann
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115 6084, USA
    J Med Primatol 31:109-19. 2002
    ..The mAbs, being natural human proteins, can be expected to have low toxicity. Passive immunization has promise to prevent intrapartum as well as milk-borne virus transmission from HIV-1-infected women to their infants...
  66. ncbi request reprint Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin
    A Razzaque Ahmed
    Center for Blistering Diseases, New England Baptist Hospital, Boston, USA
    N Engl J Med 355:1772-9. 2006
    ..Pemphigus vulgaris is a potentially fatal autoimmune mucocutaneous blistering disease. Conventional therapy consists of high-dose corticosteroids, immunosuppressive agents, and intravenous immune globulin...
  67. ncbi request reprint Human papillomavirus 16 and head and neck squamous cell carcinoma
    C Sloane Furniss
    Harvard School of Public Health, Department of Genetics and Complex Diseases, Boston, MA, USA
    Int J Cancer 120:2386-92. 2007
    ..We observed dose response relationships between serology titer and both risk for HNSCC and HPV16 tumor DNA. In cases, HPV16 tumor DNA and positive serology were associated with sexual history and improved disease free survival...
  68. doi request reprint Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis
    Laura A Goguen
    Department of Surgery Division of Otolaryngology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Laryngoscope 120:261-6. 2010
    ..Assess the safety and efficacy of combined antegrade and retrograde esophageal dilation (CARD) for complete esophageal stenosis following head and neck cancer (HNC) treatment. Review HNC dysphagia management...
  69. ncbi request reprint Pathogenic human monoclonal antibody against desmoglein 3
    Shih Wei Yeh
    Department of Oral Medicine, Harvard School of Dental Medicine, Boston, MA 02115, USA
    Clin Immunol 120:68-75. 2006
    ..PVMAB786 will be a valuable tool in identifying the role of Dsg3 in epithelial cell adherence and acantholysis, mechanisms of Dsg3 processing/presentation and V gene and isotype usage in PV pathogenesis...
  70. pmc Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine
    Casie Kelly-Quintos
    Harvard Medical School, 181 Longwood Ave, Boston, MA 02115, USA
    Infect Immun 74:2742-50. 2006
    ....
  71. doi request reprint A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions
    Lori J Wirth
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 1:339-48. 2008
    ..Treatment with celecoxib in subjects with OPLs favorably modulates the primary mediator of cyclooxygenase-2 activity, PGE(2), after 12 weeks...
  72. pmc Genetic variation in the vitamin C transporter, SLC23A2, modifies the risk of HPV16-associated head and neck cancer
    Alyce A Chen
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Carcinogenesis 30:977-81. 2009
    ..4; 95% CI = 3.6-15.1). These results suggest that SLC23A2 genetic variation alters HPV16-associated HNSCC while also highlighting the important role of citrus exposure in this disease...
  73. doi request reprint Polymerase chain reaction detection of HPV in squamous carcinoma of the oropharynx
    Elin S Agoston
    Dept of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Clin Pathol 134:36-41. 2010
    ..However, it is imperative that appropriate sensitivity controls be in place for such assays...
  74. ncbi request reprint Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris
    Abdul Kader El Tal
    Department of Medicine, New England Baptist Hospital, Harvard School of Dental Medicine, Boston, Massachusetts 02120, USA
    J Am Acad Dermatol 55:449-59. 2006
    ..Rituximab is an anti-CD20 chimeric antibody that selectively targets B lymphocytes. Recently, it has been reported to be beneficial in treating pemphigus vulgaris...
  75. ncbi request reprint Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer
    Christopher A Sullivan
    Division of Otolaryngology, Head and Neck Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Laryngoscope 114:1924-31. 2004
    ..The objective of this study was to describe and evaluate the efficacy of an endoscopic technique for the management of postchemoradiation hypopharyngeal stenosis in head and neck cancer patients...
  76. ncbi request reprint Adjuvant post-operative chemoradiotherapy in head and neck cancer: a standard of care?
    Marshall R Posner
    Oncologist 10:174-5. 2005
  77. ncbi request reprint Nonsurgical treatment of laryngeal cancer
    Robert I Haddad
    N Engl J Med 350:1049-53; author reply 1049-53. 2004
  78. ncbi request reprint Cetuximab and radiotherapy for head and neck cancer
    Marshall R Posner
    N Engl J Med 354:634-6. 2006
  79. pmc Hypermethylation of E-cadherin is an independent predictor of improved survival in head and neck squamous cell carcinoma
    Carmen J Marsit
    Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island 02912, USA
    Cancer 113:1566-71. 2008
    ....
  80. ncbi request reprint American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer
    David G Pfister
    American Society of Clinical Oncology, Alexandria, VA, VA 22314, USA
    J Clin Oncol 24:3693-704. 2006
    ..This guideline is intended for use by oncologists in the care of patients outside of clinical trials...
  81. pmc Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120
    Royce A Wilkinson
    Department of Chemistry and Biochemistry, Montana State University, Bozeman, 59717, USA
    J Virol 79:13060-9. 2005
    ..The difference between the predicted epitopes for b12 and F105 suggests that the unique potency of b12 may arise from its ability to avoid the interface between the inner and outer domains of gp120...
  82. ncbi request reprint Head and neck cancers
    Arlene A Forastiere
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
    J Natl Compr Canc Netw 3:316-91. 2005
  83. pmc A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck
    Carmen J Marsit
    Department of Pathology and Laboratory Medicine, Brown University, Providence, RI 02912, USA
    Clin Cancer Res 14:2371-7. 2008
    ..We also examined how this genotype was associated with the risk of HNSCC and if this genotype-phenotype association was related to patient outcome...

Research Grants15

  1. Functional Mechanisms of Antibody Inhibition of HIV-1
    Marshall Posner; Fiscal Year: 2007
    ....
  2. Functional Mechanisms of Antibody Inhibition of HIV-1
    Marshall Posner; Fiscal Year: 2007
    ..Long-term objectives will be to select constructs from in vitro testing for further testing in non-human primate models of prevention and therapeutics. ..
  3. HUMAN MONOCLONAL ANTIBODIES TO STUDY AND TREAT HIV
    Marshall Posner; Fiscal Year: 2003
    ..We will also study long term non-progressors and early progressors to assess the relationship of antibody to intact PI virions to control of disease as a basis for larger more powerful evaluations. ..